DexCom's stock rose over 15% after beating Q1 revenue expectations and announcing a $750 million stock buyback plan. Despite missing EPS estimates, the company maintained its full-year revenue guidance and adjusted margins.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing